ESC/EAS 2019: dyslipidaemias
International ESC/EAS Current
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach F, et al. Eur Heart J. 2020;41:111–188
DOI 10.1093/eurheartj/ehz455 · Summary checked against the source: 2026-11
Still the main ESC/EAS lipid guideline; the 2025 focused update adds to it (SCORE2, bempedoic acid, ACS, Lp(a), HIV, cancer). Pages are from Eur Heart J 2020;41:111–188.
At a glance
- "Lower is better": LDL-C goals fall with risk: very high <1.4 mmol/L (55 mg/dL) and ≥50% reduction; high <1.8 (70); moderate <2.6 (100); low <3.0 (116). [Table 7 · p. 133]
- Treatment ladder: high-intensity statin to the maximum tolerated dose → add ezetimibe → add a PCSK9 inhibitor. [I, A; I, B; I, A · p. 145]
- Measure Lp(a) at least once in every adult: >180 mg/dL (>430 nmol/L) carries a risk like heterozygous FH. [IIa, C · p. 119]
- Imaging can reclassify risk: significant plaque on angiography or CT, or carotid plaque, = very high risk; CAC >100 = high or very high. [Table 4 · p. 125]
- TG 135–499 mg/dL on a statin in high-risk patients: icosapent ethyl 2 g twice daily. [IIa, B · p. 119]
Risk categories and goals
| Risk | Who | LDL-C goal |
|---|---|---|
| Very high | Documented ASCVD (clinical or unequivocal on imaging); diabetes with target-organ damage, ≥3 major risk factors, or type 1 for >20 years; eGFR <30; SCORE ≥10%; FH with ASCVD or another major risk factor | <1.4 mmol/L (<55 mg/dL) and ≥50% reduction |
| High | Markedly raised single risk factor (TC >8 mmol/L, LDL-C >4.9 mmol/L [190 mg/dL], BP ≥180/110); FH without other risk factors; eGFR 30–59; diabetes ≥10 years without organ damage; SCORE 5–<10% | <1.8 mmol/L (<70 mg/dL) and ≥50% reduction |
| Moderate | Young diabetes (type 1 <35, type 2 <50 years, <10 years' duration, no risk factors); SCORE 1–<5% | <2.6 mmol/L (<100 mg/dL) |
| Low | SCORE <1% | <3.0 mmol/L (<116 mg/dL) |
Secondary goals: non-HDL-C <2.2, 2.6, 3.4 mmol/L (85, 100, 130 mg/dL) and apoB <65, 80, 100 mg/dL for very-high, high and moderate risk. No TG goal, but <1.7 mmol/L (150 mg/dL) means lower risk. Adapted from ESC/EAS 2019 Table 4, Table 7 and Figure 4B [p. 125, 133, 147]
Treatment algorithm
flowchart TD
A["Total CV risk assessment (Table 4)<br/>Baseline LDL-C"] --> M["Low or moderate risk, selected patients:<br/>risk modifiers, imaging, reclassification"]
A --> I{"Drug therapy indicated?<br/>(Table 5)"}
M --> I
I -->|No| L["Lifestyle advice"]
I -->|Yes| G["Define treatment goal (Table 7)"]
G --> S["High-potency statin at the highest<br/>recommended or tolerated dose"]
S --> Q1{"LDL-C goal reached?"}
Q1 -->|Yes| F1["Follow-up yearly<br/>(or more often)"]
Q1 -->|No| E["Add ezetimibe"]
E --> Q2{"LDL-C goal reached?"}
Q2 -->|Yes| F2["Follow-up yearly<br/>(or more often)"]
Q2 -->|No| P["Add PCSK9 inhibitor:<br/>secondary prevention (very high risk);<br/>FH with another major risk factor"]
Q2 -->|No| P2["Consider PCSK9 inhibitor:<br/>primary prevention, very high risk without FH"]
Adapted from ESC/EAS 2019 Figure 4A [p. 147]
| Recommendation | Class, level |
|---|---|
| High-intensity statin up to the highest tolerated dose to reach the goal | I, A |
| Not at goal on maximal statin: add ezetimibe | I, B |
| Secondary prevention, very high risk, not at goal on statin + ezetimibe: add a PCSK9 inhibitor | I, A |
| FH at very high risk (ASCVD or another major risk factor) not at goal: PCSK9 inhibitor | I, C |
| Primary prevention, very high risk without FH, not at goal: PCSK9 inhibitor may be considered | IIb, C |
| Statin not tolerated at any dose: ezetimibe | IIa, C |
Adapted from ESC/EAS 2019 recommendations for pharmacological LDL-C lowering [p. 145]
Other key recommendations
- Lp(a) once in a lifetime. [IIa, C · p. 119]
- Hypertriglyceridaemia: statins first; in high-risk patients with TG 1.5–5.6 mmol/L (135–499 mg/dL) despite a statin, icosapent ethyl 2 g twice daily. [IIa, B · p. 119]
- FH at very high risk, primary prevention: ≥50% reduction and LDL-C <1.4 mmol/L. [IIa · p. 119]
- Older people: statins for primary prevention by risk up to 75; may be considered above 75 if at high risk. [I; IIb · p. 119]
- Type 2 diabetes: very high risk <1.4 mmol/L, high risk <1.8 mmol/L, both with ≥50% reduction; statins for type 1 diabetes at high or very high risk. [I · p. 119]
- Drug treatment of TG may be considered only in high-risk patients with TG >2.3 mmol/L (200 mg/dL) despite lifestyle. [p. 145]
- Familial combined hyperlipidaemia: suspect with apoB >120 mg/dL + TG >1.5 mmol/L and a family history of premature CVD. [p. 148]
Clinical pearls
- Very high risk: <55 mg/dL (1.4 mmol/L) and ≥50% fall. Recurrent event within 2 years on maximal therapy: <40 mg/dL may be considered.
- Statin → ezetimibe → PCSK9 inhibitor.
- LDL-C ≥4.9 mmol/L (190 mg/dL) = high risk on its own; think FH (Dutch Lipid Clinic Network score).
- Lp(a) is genetically determined: measure once.
Classes and levels of evidence
How ESC/EAS 2019 grades its recommendations. Adapted from ESC/EAS 2019 Tables 1 and 2 [p. 117]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| Class I | Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective | is recommended or is indicated |
| Class IIa | Weight of evidence or opinion is in favour of usefulness or efficacy | should be considered |
| Class IIb | Usefulness or efficacy is less well established by evidence or opinion | may be considered |
| Class III | Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful | is not recommended |
| Level | Meaning |
|---|---|
| Level A | Data from multiple randomised clinical trials or meta-analyses |
| Level B | Data from a single randomised clinical trial or large non-randomised studies |
| Level C | Consensus of expert opinion and/or small studies, retrospective studies, registries |
Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.